The Swedish healthcare payer system is highly decentralised, with 21 self-governed County Councils, each with its own administrative set up for management of drug procurement, use and cost control. Having a drug included in the national reimbursement scheme is only the first step in achieving full access to the Swedish market.
A pharmaceutical company must next convince each regional drug committee of the value of the drug, and provide proof that including it will have a reasonable and manageable impact on the regional payers’ budgets. Increasingly, payers require real-world data confirming the alleged benefits of the reimbursed drug.
Sweden’s Payer Stakeholders
NATIONAL DENTAL AND PHARMACEUTICAL BENEFITS AGENCY (TLV)
The Swedish government subsidises prescription medicines and medical device consumables within a high-cost threshold
through funding of the County Councils’ budgets. Medicines used for in-patient care are paid in full by the County Councils.
The National Dental and Pharmaceutical Benefits Agency (TLV) determines medicines to be subsidised and included in the
high-cost threshold. The high-cost threshold refers to the system in which the patient pays a gradually decreasing portion of
the medicine or consumable cost prescribed by the doctor. The maximum cost for a patient in the high-cost threshold system
is 2,200 SEK during a 12-month period. The State finances the County Councils’ expenses for prescription medicines that are
covered by the reimbursement scheme through an annual grant.
To achieve reimbursement of a drug in Sweden, the pharmaceutical company must submit an application to the TLV, stating
the proposed price of the product and providing health economic documentation. Companies frequently include an analysis
of the drug’s impact on the healthcare system. TLV prepares a dossier for presentation to the Pharmaceutical Benefits Board,
comprised of community clinical experts, which renders a decision regarding reimbursement.
The company’s application is approved if TLV determines the requested price is justified and if the pharmaceutical product
delivers value in terms of improved health, often measured by Quality Adjusted Life Years (QALY). The reimbursement
decision is based on value, and Sweden often applies the Value-Based Pricing of pharmaceuticals. TLV regularly reviews the
reimbursement status of medicines to determine if they should remain in the reimbursement system. A decision by TLV may
be appealed in an administrative court of law.
Once a drug clears the reimbursement hurdle at the national level in Sweden, the company must next convince the County Councils
to adopt it as well. The Councils are the actual payers of the reimbursed medicines, and the degree and rate of a drug’s local uptake
in the reimbursement scheme may vary between regions. County councils have different budget-planning mechanisms and varying
interpretations of TLV assessments.
Important Points to Keep in Mind
The influence of the County Councils in the reimbursement decision process can be significant, especially if it considers new,
TLV is working to find collaboration models with the Swedish Association of Local Authorities and Regions (SALAR) to begin price
negotiations, which today are not allowed for drugs included in the reimbursement scheme.
The Swedish Process for Managed Introduction of New Drugs headed by the New Therapies (NT) Council of SALAR is a collaboration
model that includes not only price negotiations, but also a standardised protocol for the introduction and follow up of actual clinical
outcome and risk-sharing agreements.
Implications for Industry
Market access in Sweden requires that companies successfully prove and communicate the added benefits of a drug in several
dimensions: clinical outcomes, cost effectiveness and budget impact.
It is critical for companies to have a communications partner familiar with market access in Sweden, and with the necessary
expertise to successfully target and meet payers’ needs both on national and regional levels.
for a complimentary 30-minute consultation
Music is considered a universal language—an art form used to unite people all over the world. To celebrate the holidays this year, GLOBALHealthPR is sharing favorite songs from our partners around the world. From raps and mashups to traditional carols, check out our...
We called on GLOBALHealthPR partners from three key markets affected by the Implant Files. For their take on the immediate and forward-looking impacts, download the strategy brief. Download the full strategy...
The Global Guide to Pharma Marketing Codes Vol.4 Book 3 is available...
The Global Guide to Pharma Marketing Codes Vol.4 Book 2 is available...
The Global Guide to Pharma Marketing Codes Vol.4 Book 1 is available for download....
GLOBALHealthPR, the world’s largest partnership of independent health and life-science communications agencies, today announced its co-founder and chair, John J. Seng, has been awarded the 2018 SAM (Science And Medicine) Award by The Progeria Research Foundation (PRF). Seng received the honor for his contributions towards finding the cause, treatment and cure for children with Progeria, a rare, fatal genetic condition of accelerated ageing in children. Seng accepted the recognition on Saturday, April 28, at PRF’s Night of Wonder bi-annual gala in Boston.